Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 14/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 14/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.64 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.64 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.64 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.64 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.64 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.61 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21407358 | 0.87 | HDAC6 (0.75) | HDAC4HDAC6HDAC1HDAC5HDAC3 | |
| SCHEMBL20593260 | 0.84 | HDAC4 (0.79) | HDAC4HDAC6HDAC1HDAC5HDAC8 | |
| SCHEMBL19437204 | 0.81 | HDAC4 (0.79) | HDAC4HDAC6HDAC1HDAC5HDAC3 | |
| SCHEMBL20593420 | 0.81 | HDAC4 (0.91) | HDAC4HDAC6HDAC1HDAC5HDAC8 | |
| SCHEMBL14645445 | 0.81 | HDAC4 (1.00) | HDAC4HDAC6HDAC1HDAC8 | |
| SCHEMBL20593765 | 0.81 | HDAC6 (0.69) | HDAC4HDAC6HDAC1HDAC5HDAC3 | |
| SCHEMBL20838112 | 0.79 | HDAC4 (0.74) | HDAC4HDAC6HDAC1HDAC8 | |
| SCHEMBL14918623 | 0.79 | HDAC6 (0.65) | HDAC4HDAC6HDAC1HDAC5HDAC3 | |
| SCHEMBL19745500 | 0.78 | HDAC6 (1.00) | HDAC4HDAC6HDAC1HDAC5HDAC3 | |
| SCHEMBL18824431 | 0.78 | HDAC4 (0.69) | HDAC4HDAC6HDAC1HDAC5HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2729454-B1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2015-09-16 | — | — | EP | claimed |
| US-9056843-B2 | Trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2015-06-16 | — | — | US | claimed |
| US-20140142105-A1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2014-05-22 | — | — | US | claimed |
| EP-2729454-A1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2014-05-14 | — | — | EP | claimed |
| CN-103764635-A | Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease | NOVARTIS AG | 2014-04-30 | — | — | CN | claimed |
| WO-2013008162-A1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2013-01-17 | — | — | WO | claimed |
| EP-2729454-B1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2015-09-16 | — | — | EP | disclosed |
| EP-2729454-B1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2015-09-16 | — | — | EP | disclosed |
| US-9056843-B2 | Trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2015-06-16 | — | — | US | disclosed |
| US-9056843-B2 | Trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2015-06-16 | — | — | US | disclosed |
| US-9056843-B2 | Trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2015-06-16 | — | — | US | disclosed |
| US-20140142105-A1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2014-05-22 | — | — | US | disclosed |
| US-20140142105-A1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2014-05-22 | — | — | US | disclosed |
| US-20140142105-A1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2014-05-22 | — | — | US | disclosed |
| EP-2729454-A1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2014-05-14 | — | — | EP | disclosed |
| CN-103764635-A | Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease | NOVARTIS AG | 2014-04-30 | — | — | CN | disclosed |
| WO-2013008162-A1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2013-01-17 | — | — | WO | disclosed |
| WO-2013008162-A1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2013-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142105-A1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | HDAC4, HDAC5, HDAC6 | HDAC4 1/4885HDAC6 3/4885HDAC1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.